HC Wainwright reiterated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) in a report released on Wednesday morning, Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2024 earnings at ($0.29) EPS.
Oncolytics Biotech Stock Performance
Shares of NASDAQ:ONCY opened at $0.99 on Wednesday. The business has a fifty day moving average of $1.01 and a 200-day moving average of $1.05. Oncolytics Biotech has a twelve month low of $0.85 and a twelve month high of $2.49. The firm has a market cap of $76.09 million, a PE ratio of -3.30 and a beta of 1.91.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. During the same quarter in the prior year, the company earned ($0.09) earnings per share. On average, analysts anticipate that Oncolytics Biotech will post -0.29 EPS for the current fiscal year.
Institutional Inflows and Outflows
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- High Flyers: 3 Natural Gas Stocks for March 2022
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Insider Buying Explained: What Investors Need to Know
- MarketBeat Week in Review – 8/19 – 8/23
- Canadian Penny Stocks: Can They Make You Rich?
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.